pharmaceutical financing market

Newsletter

No.3, Issue IV. March 2016 Published: 7 April 2016



News, current issues

- Legislations come into force between 01/02/2016 and 01/03/2016: there was no modification during this period
- ARTICLE: "The National Health Insurance Fund's data service activity the "Public Data Public Treasure" link
- NEWS: "Orban agreed the restructure of healthcare " link
- NEWS: "What will happen to the hospitals? the Secretary of State spoke" link
- NEWS: "Swedish industry wants European medicines agency if UK quits EU" link
- NEWS: "Setback is coming in pharmaceutical acquisitions?" link
- NEWS: "Europe launches new fast approval scheme for promising drugs" link
- NEWS: "Ten thousand beds will be transferred from healthcare to social system" link

Macro approach to financing healthcare and medicinal products

Balance of the Health Insurance Fund

					Billion HUF
		2016 original	2016		
Health Security Fund	2015. I-XII.	appropriation	I. month	% of appropriation	% of last year
Total of Budgetary Expenditures	1 955,3	1 963,7	158,9	97,1%	102,8%
Curative preventive provisions	960,6	982,4	78,1	95,4%	105,6%
Medicine subsidies	326,2	305,1	26,5	104,4%	101,8%
Medicine subsidies (pharmacy)	310,6	231,4	26,3	136,4%	101,2%
Total of Budgetary Revenues	1 925,4	1 963,7	179,7	109,8%	105,6%
Social Security Contributions	1 223,4	1 417,0	134,1	113,6%	119,8%
Contribution of Pharmaceutical Manufacturers and Wholesalers	65,3	58,0	4,8	98,3%	94,5%
Balance	-29,9	0,0	20,8		134,3%

Budget impact simulation models

Illness/subgroup-specific budget impact analysis that reflect the actual uses, and simulation platforms built upon these analysis are becoming more important role in domestic acceptance mechanism. The simulation mo-dels built on National Health Insurance data offer well understood and controllable dimension for the expected budget impact calculations for the decision maker.

More about the service: link

Product offering

In expenditures and revenues of 2016 budget, there is 2,77% increase compared to appropriation of 2015 and 0,43% increase compared to fulfilment of 2015. The central budget contribution is planned to be less with 26,5% than last year fulfilment, and this gap is filled with the 18,2% higher social security contribution (218 billion HUFs). The medicine subsidies plan is lower with 21,2 billion HUFs than last year expenses, but higher with 7 billion HUFs than the last year's original appropriation. In the first month of 2016 the Health Security Fund produced a 12,69% surplus due to the higher social security contributions (+13,6%). Medicine subsidies shows 4,4% surplus as a result of the medicines' higher turnover particularly that reimbursement based on special permission.

Changes to subsidised medicinal product categories

Changes in the public drug list	2015 Oct.	2015 Nov.	2015 Dec.	2016 Jan.	2016 Feb.	2016 Mar.	2016
Number of new products	34	23	8	28	9	19	56
Number of new Al	2	3	1	5	0	1	6
Number of delisted products	40	18	20	27	18	9	54
Prices							
Decrease	120	8	0	31	3	5	39
Increase	0	0	0	0	0	0	0

Dynamics of the sales/circulation of prescription-only-medicine

Changes in the public 2015 2015 2015 2016 2016 2016 2016 Irug list Oct. Nov Dec. Jan Feb. Mar Reimbursement Decrease 389 0 1 6 47 5 40 56 0 0 24 2 0 26 Increase Co-payment 171 12 77 Decrease 0 67 4 6 Increase 313 0 0 16 0 1 17

Source: Healthware analysis based on OEP-PUPHA data

109% 106%

104%



Source: Healthware analysis based on OEP's data

Pharmacy reimbursement turnover

comparing to same period last year

109% 107%

104%

118% 113%

108%

105%

106%

105%

Prescription drugs' DOT turnover in 2015 was 1,04% higher than in 2014, so the trend of drug consumption is still increasing, but in slower rate than in 2014 (2,74%) or 2013 (2,23%); while the reimbursement turnover was higher with 7,44%. The average reimbursement per DOT was higher with 6,34% than the 2014's average. New innovative reimbursement decisions were made in 2014 and 2015 generated 3,1% and 0,65% of annual reimbursement turnover, while only 0,4% of annual DOT turnover. Drug sales in the first month of 2016 was 2,72% lower than the same period last year, while the average reimbursement per DOT increased with 6,44%. The reimbursement turnover was higher with 3,54% for this period compared to last year.

Subscribe Unsubscribe

Source: Healthware analysis based on OEP's data

pharmaceutical market

No.3, Issue IV. March 2016 Published: 7 April 2016



Market data

Newsletter

_	_						_	
2015	EMA	OGYI	2015 - Q4	EMA	OGYI	January 2016	EMA	OGY
New brands	90	185	New brands	22	41	New brands	9	9
New SKUs	873	2 149	New SKUs	149	479 Source: Heal	New SKUs thware analysis based on C	86 DGYI's and EM	77 A's dat
OP10 DISTR	BUTOR	by all re	eimburseme	ent paid in .	January	2016		
			TOP 10 - DISTRI	BUTOR			Reimburse	ement
			Novartis Hungá	ria Kft.			2 363 735 559 HUF	
			SANOFI-AVENT	IS Zrt.			1 608 901 385 HU	
			EGIS Gyógyszer	gyár Zrt.			1 295 975 65	53 HUI
			Richter Gedeon	Vegyészeti Gyá	r NyRt.		1 239 105 13	34 HUI
13 227 441 625	12 192 76	4013	TEVA Gyógysze	rgyár Zrt.			1 179 463 92	22 HUI
HUF	HUF		Pfizer Kft.				1 101 600 06	59 HUF
			Novo Nordisk H	ungária Kft.			942 703 28	82 HUF
			Lilly Hungaria K	ft.			837 260 22	10 HUF
			Janssen-Cilag G	byógyszerkeresk	edelmi Ma	rketing Szolgáltató Ki	814 602 55	55 HUF
			Sandoz Hungári	a Kereskedelmi	Kft.		809 416 24	44 HUF
OP10 BRAN	D by all r	reimbu	rsement pai	d in Januar	y 2016	es turnover that pharmacle	s produced fro	om POK
OP10 BRAN	D by all r	reimbui	rsement pai	d in Januar	y 2016	es turnover that pharmacie	Reimburse	ement
OP10 BRAN	D by all r	reimbui	TOP 10 - BRAND	d in Januar	y 2016	es turnover that pharmacie	Reimburse	ement 98 HUI
OP10 BRAN	D by all r	reimbui	TOP 10 - BRAND CLEXANE GLIVEC	d in Januar Distributor SANOFI-AVEN Novartis Hung	y 2016 TIS Zrt.	es turnover that pharmacie	Reimburse 531 963 7 520 587 6	ement 98 HUI 84 HUI
OP10 BRAN	D by all r	reimbui	TOP 10 - BRAND CLEXANE GLIVEC XEPLION	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag	y 2016 ITIS Zrt. gária Kft. Gyógyszerl	es turnover that pharmacie kereskedelmi Market	Reimburse 531 963 79 520 587 6 433 129 74	ement 98 HUI 84 HUI 49 HUI
OP10 BRAN	D by all r	reimbu	TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In	y 2016 ITIS Zrt. Gyógyszeri gelheim Ph	kereskedelmi Market arma Gesellschaft m.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 50	ement 98 HUI 84 HUI 49 HUI 68 HUI
OP10 BRAN	ID by all r	reimbui	TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN	y 2016 ITIS Zrt. tária Kft. Gyógyszerl gelheim Ph ITIS Zrt.	s tumover that pharmacie kereskedelmi Market arma Gesellschaft m.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 50 334 050 1	ement 98 HUI 84 HUI 49 HUI 68 HUI 89 HUI
OP10 BRAN 21918982005 HUF	D by all r	reimbui 3 633	TOP 10- BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria	y 2016 ITIS Zrt. gária Kft. Gyógyszerl gelheim Ph ITIS Zrt. Kft.	s tumover that pharmacie kereskedelmi Market arma Gesellschaft m.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3	ement 98 HUI 84 HUI 49 HUI 68 HUI 89 HUI 52 HUI
OP10 BRAN 21 918 982 005 HUF	D by all r	s 633	TOP 10- BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung	y 2016 TIS Zrt. gária Kft. Gyógyszerl gelheim Ph ITIS Zrt. Kft. gária Kft.	kereskedelmi Market arma Gesellschaft m.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6	ement 98 HUI 84 HUI 49 HUI 68 HUI 89 HUI 52 HUI 88 HUI
OP10 BRAN	350122 HUI	3 633	rsement pai TOP 10 - BRAND CLEXANE GUVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft.	y 2016 TIS Zrt. gária Kft. Gyógyszeri gelheim Ph TIS Zrt. Kft. gária Kft.	s tumover that pharmacie kereskedelmi Market arma Gesellschaft m.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0	ement 98 HUI 84 HUI 49 HUI 68 HUI 89 HUI 52 HUI 38 HUI 38 HUI
OP10 BRAN 21918982005 HUF	D by all r	3 633	TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec Hi	y 2016 ITIS Zrt. áária Kft. Gyógyszerl gelheim Ph ITIS Zrt. Kft. áária Kft. ungary Kft.	kereskedelmi Market arma Gesellschaft m.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 11 283 928 3 272 224 6 267 068 0 265 269 4	ement 98 HUI 84 HUI 49 HUI 68 HUI 89 HUI 52 HUI 88 HUI 38 HUI 14 HUI
OP10 BRAN	D by all r	3 633	rsement pai TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec Hi Novo Nordisk	y 2016 ITIS Zrt. tária Kft. Gyógyszerl gelheim Ph ITIS Zrt. Kft. tária Kft. ungary Kft. Hungária Kf	kereskedelmi Market arma Gesellschaft m. ft.	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1	ement 98 HUI 84 HUI 49 HUI 68 HUI 52 HUI 52 HUI 38 HUI 14 HUI 53 HUI
OP10 BRAN	350122 HUI	a 633	rsement pai TOP 10- BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec Hi Novo Nordisk	y 2016 TIS Zrt. tária Kft. Gyógyszeri gelheim Ph TIS Zrt. Kft. tária Kft. ungary Kft. Hungária K ted on the sale	kereskedelmi Market arma Gesellschaft m. ft.	Reimburse 531 963 7 520 587 6 433 129 7 334 050 1 283 928 3 272 224 6 267 068 0 267 068 0 265 269 4 265 259 4 265 259 4	ement 98 HUI 84 HUI 89 HUI 68 HUI 89 HUI 52 HUI 38 HUI 14 HUI 53 HUI 53 HUI 53 HUI
OP10 BRAN	D by all f	nburser	rsement pai TOP 10 - BRAND CLEXANE CLEXANE CLEVEC XEPLION SPIRIVA LANTUS LANTUS LANTUS LANTUS LANTUS LANTUS LANTUS SUTENT TECFIDERA LEVEMIR Source: Heol ment paid in	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lill yHungaria Novartis Hung Prizer Kft. Biogen Idec H Novo Nordisk Ithware analysis bass	y 2016 TIS Zrt. ária Kft. Gyógyszerl gelheim Ph TIS Zrt. Kft. iária Kft. ungary Kft. Hungária K <i>ed on the sale</i> 016	kereskedelmi Market arma Gesellschaft m. ft. es turnover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 5 produced fro	ement 98 HUI 84 HUI 49 HUI 68 HUI 89 HUI 52 HUI 52 HUI 53 HUI 14 HUI 53 HUI 53 HUI
OP10 BRAN	D by all f	nburser	TOP 10 - BRAND CLEXANE CLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea nent paid in TOP 10 - ATC	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec Hi Novo Nordisk thware analysis bas January 20 International no	y 2016 ITIS Zrt. Gyógyszerf gelheim Ph ITIS Zrt. Kft. tária Kft. ungary Kft. Hungária K Hungária K ed on the sole 016 n-proprieta	kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 5 produced fro Reimburse	ement 98 HUI 84 HUI 49 HUI 88 HUI 88 HUI 38 HUI 38 HUI 53 HUI 53 HUI 53 HUI 53 HUI
OP10 BRAN	D by all n	nburser	rsement pai TOP 10 - BRAND CLEXANE CLEXANE CLEVANE SUPEITON SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea Nent paid in TOP 10 - ATC B0JABOS	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Prizer Kft. Biogen Idec H Novo Nordisk thware analysis bass January 20 International no enoxaparin	y 2016 TIS Zrt. cária Kft. Gyógyszeri geiheim Ph TIS Zrt. Kft. ungary Kft. ungary Kft. Hungária K sed on the sale 016 n-proprieta	kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 5 produced fro Reimburse 531 963 7	ement 98 HUU 84 HUU 49 HUU 88 HUU 88 HUU 38 HUU 38 HUU 53 HUU 53 HUU 53 HUU 98 HUU
OP10 BRAN	D by all n	nburser	rsement pai TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea nent paid in TOP 10 - ATC B01AB05 V06D	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec H Novo Nordisk thware analysis bas January 20 International no enoxaparin other nutrients	y 2016 TIS Zrt. cária Kft. Gyógyszeri gelheim Ph TIS Zrt. Kft. Kft. ungary Kft. Hungária K Hungária K ed on the sole 016 n-proprieta	kereskedelmi Market kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 265 269 4 265 259 4 265 25	ement 98 HUI 98 HUI 49 HUI 68 HUI 88 HUI 52 HUI 88 HUI 14 HUI 53 HUI 14 HUI 53 HUI 98 HUI 41 HUI
21918982005 HUF OP10 ATC b	D by all n	nburser	rsement pai TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea TOP 10 - ATC B01AB05 VOGD	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec H Novo Nordisk thware analysis bass January 20 International no enoxaparin other nutrients imatinib	y 2016 TIS Zrt. tária Kft. Gyógyszeri gelheim Ph TIS Zrt. Kft. tíft. tíft. ungary Kft. Hungária K Hungária K Hungária K hungária K hungária K hungária K	kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 267 068 0 265 269 4 265 259 4 265 259 4 265 554 1 s produced fro 531 963 7 522 978 5 522 978 5 522 978 5	ement 98 HUI 88 HUI 88 HUI 88 HUI 88 HUI 38 HUI 14 HUI 53 HUI 14 HUI 98 HUI 98 HUI 41 HUI 98 HUI 41 HUI
0P10 BRAN 21918982005 HUF	D by all f	nburser	rsement pai TOP 10 - BRAND CLEXANE GLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea TOP 10 - ATC B01AB05 -V06D L01XE01 N05AX13	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hungaria Pfizer Kt. Biogen Idec Hi Novo Nordisk I January 20 International no enoxaparin other nutrients matinib paliperidone	y 2016 TIS Zrt. cária Kft. Gyógyszeri gelheim Ph TIS Zrt. Kft. cária Kft. Hungária K Hungária K ed on the sale 016 n-proprieta	kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 12 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 s produced fre 511 963 7 522 978 5 520 587 6 500 711 7	ementi 98 HUI 84 HUI 49 HUI 68 HUI 88 HUI 88 HUI 88 HUI 53 HUI 53 HUI 53 HUI 53 HUI 98 HUI 98 HUI 98 HUI 98 HUI 51 HUI 51 HUI
OP10 BRAN 21918982005 HUF	D by all f	nburser	TOP 10 - BRAND CLEXANE CLEXANE CLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea ment paid in TOP 10 - ATC	d in Januar Distributor SANOFI-AVEN Novartis Hung Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Pfizer Kft. Biogen Idec Hi Novo Nordisk thware analysis bas January 20 International no	y 2016 TIS Zrt. cária Kft. Gyógyszerf gelheim Ph TIS Zrt. Kft. cária Kft. ungary Kft. Hungária Kft. Hungária K sed on the sole 016 n-proprieta	kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 s produced fre Reimburse	ement 98 HUJ 49 HUJ 68 HUJ 89 HUJ 52 HUJ 38 HUJ 38 HUJ 38 HUJ 53 HUJ 53 HUJ 53 HUJ 53 HUJ
OP10 BRAN	D by all f	nburser	rsement pai TOP 10 - BRAND CLEXANE CLIVEC XEPLION SPIRIVA LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea TOP 10 - ATC B01AB05 V06D L01XE01	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Ny Autoris Hungaria Ny Autoris Hungaria Prizer Kft. Biogen Idec H Novo Nordisk Ithware analysis bass January 20 International no enoxaparin other nutrients imatinib paliperidone	y 2016 TTIS Zrt. cária Kft. Gyógyszeri gelheim Ph TTIS Zrt. Kft. ungary Kft. Hungária K Hungária K ted on the sole 016 n-proprieta	kereskedelmi Market arma Gesellschaft m. ft. es tumover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 12 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 5 produced fro 521 963 7 522 978 5 520 587 6 500 711 7	ement 98 HU 49 HU 68 HU 89 HU 52 HU 88 HU 52 HU 88 HU 53 HU 53 HU 98 HU 98 HU 41 HU 98 HU 51 HU
OP10 BRAN	D by all n	nburser	rsement pai TOP 10 - BRAND CLEXANE CLEXANE CLEXANE SUPEITON SPIRIVA LANTUS LANTUS HUMULIN TASIGNA SUTENT TECFIDERA LEVEMIR Source: Hea Nent paid in TOP 10 - ATC B01AB05 VOGD L01XE01 NOSAX13 C10AA07	d in Januar Distributor SANOFI-AVEN Novartis Hung Janssen-Cilag Boehringer In SANOFI-AVEN Lilly Hungaria Novartis Hung Prizer Kft. Biogen Idec H Novo Nordisk Ithware analysis bass January 20 International no enoxaparin other nutrients imatinib paliperidone rosuvastatin	y 2016 TIS Zrt. cária Kft. Gyógyszeri geiheim Ph TIS Zrt. Kft. ungary Kft. Hungária K sed on the sale 016 n-proprieta	kereskedelmi Market arma Gesellschaft m. ft. es umover that pharmacie	Reimburse 531 963 7 520 587 6 433 129 7 347 447 5 334 050 1 283 928 3 272 224 6 267 068 0 265 269 4 245 554 1 5 produced from Reimburse 531 963 7 522 978 5 520 587 6 520 587 6 520 587 6 520 587 6 520 711 7 415 097 8	emeni 98 HU 88 HU 49 HU 68 HU 89 HU 52 HU 88 HU 38 HU 14 HU 53 HU 98 HU 41 HU 84 HU 51 HU 51 HU

insulin glargine

insulin (human)

nilotinib

perindopril and diuretics

Source: Healthware analysis based on the sales turnover that pharmacies produced from POM

Average number of **medical sales reps**; 01/2016



Drug reimbursement by legal title; 01/2016



Source: Healthware analysis based on the sales

TOP10 ATC by number of patients in January 2016

TOP 10 - ATC	International non-proprietary name (INN)	Patients
B01AC06	acetylsalicylic acid	346 912
C09BA04	perindopril and diuretics	286 096
C08CA01	amlodipine	261 024
C07AB12	nebivolol	243 602
C10AA05	atorvastatin	226 676
C10AA07	rosuvastatin	222 587
M04AA01	allopurinol	203 185
A11CC05	colecalciferol	195 750
C09AA04	perindopril	175 750
A02BC02	pantoprazole	175 699
Source: Heal	thware analysis based on the sales turnover that pharmacies r	produced from POM

Epidemic spreading modelled with network processes — Case study

A10AF04

A10AB01

C09BA04

L01XE08

The network science appears at more and more fields of science as a modelling method recently. The network processes are based on graph theory. In our case study we attend to network processes of epidemic spreading. Predictions could be made with simulations constructed on several models, that helps to get acquainted better with features of a given epidemic. The models are complex because we would like to model the dynamics of the population as realistically as possible. Thus we have to construct a few more parameters and more complex mathematical methods to the given model. One pillar of the epidemic spreading is the SIR model. Previously mentioned tools of the graph theory forms base of the model.



We can see a graph with three nodes on the figure above. The nodes denote the people and the edges denote the connection between them. Hence nodes of the graph have three potential states in this case: S (susceptible), I (infected) and R (recovered). On the figure the arrows indicate the direction of infection. At first there is one infected patient and then disease spread further, finally everybody gets immune.

Several other models could be constructed due to spread of the infection, based on the statuses of nodes. There is a case when it is not possible to get immune, but may get recovered from the given disease, it called SIS model. The Ebola epidemic outbreak (notified in March 2014) was examined with the SEIR model. Spread of the infection was analyzed and division of the vaccines were optimized among infected countries. The assay based on data released by the WHO.

Flowchart on the right illustrates the possible states SEIR model may have [1]. In comparison with previous model, in this one ${\bf R}$ state includes dead patients also, and

341 549 216 HUF 341 454 891 HUF

305 437 243 HUF

272 224 688 HUP



a new E (exposed) state was created which includes individuals who became infectious after a latency period. Note that in this model the case of an infectious patient getting into the susceptible state again, is not examined.

Spread of the Streptococcus pneumoniae (PCV) bacterium was analyzed with SIS model in another paper [2]. This disease threats especially infants and younger children because their immune system is not able to fight the disease. The whole model is created with Markov-chains and parameters from real data are used during the simulation.

We can see that in order to get a more clear picture about dynamics of spread of disease, the modelling of epidemic spreading is a good opportunity. Before outbreak of the disease we can determine the necessary amount of vaccine the patient needs to get and the area it has to be delivered at. In Hungary there is opportunity for preparation of such a model, for instance in case of Pneumococcus, distribution of the healthy and infected individuals and number of vaccines in a given age group can be apposite base of preparing an epidemic spreading network model.

Required data for modeling of spreading of Streptococcus pneumoniae (PCV)						
Name	Description	Institute				
Number of Hungary population based on age and location	age group splitting (under 2 years old, over 65 years old, everybody else); location splitting (county, region, country-wide)	KSH (Hungarian Central Statistical Office)				
In line with Susceptible (S) knowledge	number of healthy individual, who are in Susceptible (S) state so far	ANTSZ (National Public Health and Medical Officer Service) / — OEP (National Health Insuranc Fund of Hungary)				
	number of infected patient					
Number of vaccines	number of vaccines	ANTSZ / OEP				

J.Morrow, Modeling the spread of Ebola
A. Gray, D. Greenhalgh, X. Mao, J.Pan, The SIS epidemic model with Markovian switching, J.Math.Anal.Appl. 394 (2012) 496-516.

HealthWare Consulting Ltd.